In the past year (12/1/2008-11/30/2009), 326 patients were registered onto 26 high priority, innovative, feasibility (i.e., pre-phase I, pilot) and phase 1 institutional clinical interventions. These studies reflect the efforts of 19 different OSUCCC principal investigators (Table 2) and the scientific activities of four OSUCCC programs;Experimental Therapeutics (ETP), Cancer Control (CC), Molecular Carcinogenesis and Chemoprevention (MCC) and Immunology (IMM). Patients enrolled onto these protocols are managed by the Clinical Trials Office (CTO) utilizing protocol-specific-clinical research support. Based upon the current accrual statistics for investigator-initiated therapeutic clinical trials and an estimate of approximately 40 active clinical trial participants per clinical coordinator per year, we can justify a request for 5.0 FTEs for protocol-specific clinical support in year one of the CCSG renewal (see justification above). The CTO now manages 365 open clinical trials, including 55 therapeutic trials that were authored by OSUCCC investigators. Clinical investigators at the OSUCCC are encouraged to actively pursue funding for trials through external peer review mechanisms whenever possible. Thus, a number of these investigator-initiated trials (12) are supported though the OSU phase 1 grant (UOl CA76576) or the OSU NOI grant {m^ CM62207). Trials that are not supported by external funds are eligible for Protocol-Specific Research Support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-37
Application #
8567339
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
37
Fiscal Year
2013
Total Cost
$220,850
Indirect Cost
$76,030
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Salem, Galena; Ruppert, Amy S; Elder, Patrick et al. (2015) Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. Leuk Lymphoma 56:1058-65
Niederwieser, C; Kohlschmidt, J; Volinia, S et al. (2015) Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia 29:567-75
Billingsley, Caroline C; Cohn, David E; Mutch, David G et al. (2015) Polymerase ? (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing. Cancer 121:386-94
Krok-Schoen, Jessica L; Kurta, Michelle L; Weier, Rory C et al. (2015) Clinic type and patient characteristics affecting time to resolution after an abnormal cancer-screening exam. Cancer Epidemiol Biomarkers Prev 24:162-8
Biddle, Martha J; Lennie, Terry A; Bricker, Gregory V et al. (2015) Lycopene dietary intervention: a pilot study in patients with heart failure. J Cardiovasc Nurs 30:205-12
Jin, Ming; Roth, Rachel; Rock, Jonathan B et al. (2015) The impact of tumor deposits on colonic adenocarcinoma AJCC TNM staging and outcome. Am J Surg Pathol 39:109-15
Llanos, Adana A; Pennell, Michael L; Young, Gregory S et al. (2015) No association between colorectal cancer worry and screening uptake in Appalachian Ohio. J Public Health (Oxf) 37:322-7
Nguyen, Huyen T; Jia, Guang; Shah, Zarine K et al. (2015) Prediction of chemotherapeutic response in bladder cancer using K-means clustering of dynamic contrast-enhanced (DCE)-MRI pharmacokinetic parameters. J Magn Reson Imaging 41:1374-82
Berman-Booty, Lisa D; Thomas-Ahner, Jennifer M; Bolon, Brad et al. (2015) Extra-prostatic transgene-associated neoplastic lesions in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice. Toxicol Pathol 43:186-97
Di Leva, Gianpiero; Garofalo, Michela; Croce, Carlo M (2014) MicroRNAs in cancer. Annu Rev Pathol 9:287-314

Showing the most recent 10 out of 1178 publications